

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAMPC1626

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'CAPLUS' AT 12:37:02 ON 07 DEC 2009
FILE 'CAPLUS' ENTERED AT 12:37:02 ON 07 DEC 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	271.72	544.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-39.36	-39.36

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	271.72	544.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-39.36	-39.36

FILE 'REGISTRY' ENTERED AT 12:37:15 ON 07 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 DEC 2009 HIGHEST RN 1196037-39-4
DICTIONARY FILE UPDATES: 6 DEC 2009 HIGHEST RN 1196037-39-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10527384_reply_3.str



chain nodes :
7 8 9 10 11 12 13 22 23 24 25
ring nodes :
1 2 3 4 5 6 16 17 18 19 20 21
chain bonds :
4-7 5-22 7-8 8-10 8-9 8-16 11-13 11-12 11-23 22-23 22-25 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21
exact/norm bonds :
4-7 7-8 8-10 8-9 8-16 11-13 11-12
exact bonds :
5-22 11-23 22-23 22-25 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21
isolated ring systems :
containing 1 :


G1

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS

L11 STRUCTURE UPLOADED

=> d

L11 HAS NO ANSWERS
L11 STR



G1

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 11:56:11 ON 07 DEC 2009)

FILE 'REGISTRY' ENTERED AT 11:57:52 ON 07 DEC 2009

L1	STRUCTURE UPLOADED
L2	15 S L1 SAM
L3	STRUCTURE UPLOADED
L4	14 S L3 SAM
L5	292 S L3 FULL
L6	254 S L5 AND CAPLUS/LC
L7	0 S L5 NOT L5
L8	0 S L5 NOT L5
L9	38 S L5 NOT L6

FILE 'CAPLUS' ENTERED AT 12:02:52 ON 07 DEC 2009
48 S L6

FILE 'REGISTRY' ENTERED AT 12:37:15 ON 07 DEC 2009
L11 STRUCTURE UPLOADED

=> s l11 sss sub=15 sam

SAMPLE SUBSET SEARCH INITIATED 12:37:44 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	5 TO	234
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	3 TO	163

L12 3 SEA SUB=L5 SSS SAM L11

=> s l11 sss sub=15 full

FULL SUBSET SEARCH INITIATED 12:37:49 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 115 TO ITERATE

100.0% PROCESSED 115 ITERATIONS 64 ANSWERS
SEARCH TIME: 00.00.01

L13 64 SEA SUB=L5 SSS FUL L11

=> s l13 and caplus/lc

69210847 CAPLUS/LC
L14 61 L13 AND CAPLUS/LC

=> s l13 not l14

L15 3 L13 NOT L14

=> d l15 1-3

L15 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2009 ACS ON STN
RN 777898-58-5 REGISTRY


ED Entered STN: 10 Nov 2004

CN 2-Propenoic acid, 3-[2-[[[(4-methylphenyl)sulfonyl]amino]phenyl]- (CA INDEX NAME)

MF C16 H15 N O4 S

SR Chemical Library

Supplier: Rare Chemicals GmbH



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2009 ACS ON STN

RN 777897-53-7 REGISTRY


ED Entered STN: 10 Nov 2004

CN 2-Propenoic acid, 3-[5-chloro-2-[[[(4-methylphenyl)sulfonyl]amino]phenyl]- (CA INDEX NAME)

MF C16 H14 Cl N O4 S

SR Chemical Library


Supplier: Rare Chemicals GmbH



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2009 ACS ON STN

RN 777897-37-7 REGISTRY
ED Entered STN: 10 Nov 2004
CN 2-Fropenoic acid, 3-[[3,5-dibromo-2-[[[4-methylphenyl)sulfonyl]amino]phenyl]- (CA INDEX NAME)
MF C16 H13 Br2 N O4 S
SR Chemical Library
Supplier: Rare Chemicals GmbH



PROPERTY DATA AVAILABLE IN THE 'PROE' FORMAT

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

SINCE FILE ENTRY	TOTAL SESSION
56.46	601.33
0.00	-39.36

FILE 'CAPLUS' ENTERED AT 12:38:09 ON 07 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Dec 2009 VOL 151 ISS 24
FILE LAST UPDATED: 6 Dec 2009 (20091206/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 11:56:11 ON 07 DEC 2009)

FILE 'REGISTRY' ENTERED AT 11:57:52 ON 07 DEC 2009

L1	STRUCTURE UPLOADED
L2	15 S L1 SAM
L3	STRUCTURE UPLOADED
L4	14 S L3 SAM
L5	292 S L3 FULL
L6	254 S L5 AND CAPLUS/LC
L7	0 S L5 NOT L5
L8	0 S L5 NOT L5
L9	38 S L5 NOT L6

FILE 'CAPLUS' ENTERED AT 12:02:52 ON 07 DEC 2009

L10	48 S L6
-----	---------

FILE 'REGISTRY' ENTERED AT 12:37:15 ON 07 DEC 2009

L11	STRUCTURE UPLOADED
L12	3 S L11 SSS SAM SUB=L5
L13	64 S L11 SSS FULL SUB=L5
L14	61 S L13 AND CAPLUS/LC
L15	3 S L13 NOT L14

FILE 'CAPLUS' ENTERED AT 12:38:09 ON 07 DEC 2009


=> s l14
L16 15 L14

=> d l16 ibib gi abs hitetr 1-15


L16 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:1297092 CAPLUS
DOCUMENT NUMBER: 151:490887
TITLE: Preparation of bis-aryl compounds as leukotriene C4 synthase inhibitors
INVENTOR(S): Nilsson, Peter; Katkevics, Martins; Pelman, Benjamin
PATENT ASSIGNEE(S): Bioliipox AB, Swed.
SOURCE: PCT Int. Appl., 196pp.
CODEN: PIXX2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009127822	A2	20091022	WO 2009-GB966	20090416
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JF, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, TD, TG, TH, TM, TR, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.: US 2008-71176P P 20080416				

GI




GI



AB The title compds. I [either one of D2a and D2b = D2, and the other represents C(L2Y2); Y = O, S(O)m; each of D1, D2 and D3 resp. represent CR1a, CR1b and CR1c, or each of D1, D2 and D3 may alternatively and independently represent N; ring A = (un)substituted phenylene, pyridinylene, etc.; Y1 = CH(CF3)OH, C(O)CF3, C(O)2CF3, etc.; Y2, Y3 = (un)substituted (hetero)aryl; L1 = O, C(O), (un)substituted CH2; L2, L3 = a bond, (CH2)pS, etc.; p = 0-2; m = 0-2] which are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation, were prepared E.g., a multi-step synthesis of 2-(4-butybenzamido)-5-[3-carboxy-4-(phenylsulfonylamino)phenoxy]benzoic acid, starting from 2-amino-5-hydroxybenzoic acid, was given. Exemplified compds. I were found to exhibit 50% inhibition of LTC4 synthase at a concentration of 10 µM or below (IC50 values provided for representative compds. I). Pharmaceutical compns. comprising compound I, alone or in combination with other therapeutic agent, are disclosed.

IT 1192316-00-9P 1192316-03-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
RN 1192316-00-9 CAPLUS
CN 2-Fropenoic acid, 3-[5-[4-(benzoylamino)phenoxy]-2-[[[4-butoxyphenyl)sulfonyl]amino]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 1192316-03-2 CAPLUS


CN Benzoic acid, 5-[4-[[[4-butoxyphenyl)sulfonyl]amino]-3-[[[1E)-2-carboxyethenyl]phenoxy]-2-[[[4-(1-methylethoxy)benzoyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.




IT 1192318-02-7E 1192318-06-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
RN 1192318-02-7 CAPLUS
CN 2-Fropenoic acid, 3-[5-[4-(benzoylamino)phenoxy]-2-[[[4-butoxyphenyl)sulfonyl]amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1192318-06-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Double bond geometry as shown.




L16 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:1214476 CAPLUS
DOCUMENT NUMBER: 151:528585
TITLE: Synthesis of Highly Enantioenriched 3,4-Dihydroquinolin-2-ones by 6-Exo-trig Radical Cyclizations of Axially Chiral α -Halo-ortho-alkenyl Anilides
AUTHOR(S): Guthrie, David B.; Geib, Steven J.; Curran, Dennis P.
CORPORATE SOURCE: Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, 15260, USA
SOURCE: Journal of the American Chemical Society (2009), 131(42), 15492-15500
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English


AB Radical cyclizations (Bu₃SnH, Et₃B/air, rt) of racemic α -halo-ortho-alkenyl anilides provide 3,4-dihydroquinolin-2-ones in high yield. Cyclizations of enantioenriched precursors occur in similarly high yields and with transfer of axial chirality to the new stereocenter of the products with exceptionally high fidelity (often >95%). Single and tandem cyclizations of α -halo-ortho-alkenyl anilides bearing an addnl. substituent on the α -carbon occur with high chirality transfer and high diastereoselectivity. Straightforward models are proposed to interpret both the chirality transfer and diastereoselectivity aspects. These first examples of an approach for axial chiral transfer from a reactive species in the amide to an acceptor suggest broad potential for extension both within and beyond radical reactions.

IT 1193254-49-7E
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of racemic dihydroquinolinones via radical cyclization reactions of vinyl-substituted haloacetanilides and product competition expts. to determine a rate constant for cyclization)
RN 1193254-49-7 CAPLUS
CN 2-Propenoic acid, 3-[2-[acetyl[(4-methylphenyl)sulfonyl]amino]-3,5-dimethylphenyl]-, 1,1-dimethylethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT 1193253-91-6P 1193254-02-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of racemic vinyl-substituted haloacetanilides as substrates for radical cyclization reactions to form dihydroquinolinones)
RN 1193253-91-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:533327 CAPLUS
DOCUMENT NUMBER: 149:69540
TITLE: Synthesis and biological evaluation of a series of 2-(3,4,5-trimethoxybenzoyl)-indol-3-yl acetic acid derivatives as potential agents against human leukemia K562 cells
AUTHOR(S): Romagnoli, Romeo; Baraldi, Pier Giovanni; Cruz-Lopez, Olga; Carrion, Maria Dora; Cara, Carlota Lopez; Balzarini, Jan; Fabbri, Enrica; Gambari, Roberto
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università di Ferrara, Ferrara, 44100, Italy
SOURCE: Letters in Drug Design & Discovery (2008), 5(3), 214-220
CODEN: LDDDDW; ISSN: 1875-628X
URL: http://www.ingentaconnect.com/content/ben/lddd/2008/00000005/00000003
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
OTHER SOURCE(S): CASREACT 149:69540

AB A series of 2-(3',4',5'-trimethoxybenzoyl)-indol-3-yl acetic acid derivs. 2a-g and 3a-j were synthesized and the effects of all the compds. on human leukemia K562 cell growth were investigated. The results showed that the presence of one or more electron-donating methoxy groups at 7- or 5- and 7- positions of N-Me indole ring, corresponding to compds. 3d and 3f, increased antiproliferative activity against K562 cells and induced the cell apoptosis. The results demonstrated that the methylation of the nitrogen atom of indole nucleus plays an important role for the anti-proliferative activities. Replacing the 3',4',5'-trimethoxybenzoyl functionality with a 3',4'-dimethoxybenzoyl, 4'-methoxybenzoyl or benzoyl group (compds. 3h-j, resp.) yielded inactive compds.


IT 1033562-59-2P 1033562-61-6P 1033562-63-8P
1033562-65-0P 1033562-67-2P 1033562-69-4P
1033562-71-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Synthesis and biol. evaluation of a series of 2-(3,4,5-trimethoxybenzoyl)-indol-3-yl acetic acid derivs. as potential agents against human leukemia K562 cells)
RN 1033562-59-2 CAPLUS
CN 2-Propenoic acid, 3-[2-[[[4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1193254-02-2 CAPLUS
CN 2-Propenoic acid, 3-[2-[(2-chloroacetyl)[(4-methylphenyl)sulfonyl]amino]-3,5-dimethylphenyl]-, 1,1-dimethylethyl ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



IT 1193254-12-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of racemic vinyl-substituted haloacetanilides as substrates for radical cyclization reactions to form dihydroquinolinones)
RN 1193254-12-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[(2-iodoacetyl)[(4-methylphenyl)sulfonyl]amino]-3,5-dimethylphenyl]-, 1,1-dimethylethyl ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.

Double bond geometry as shown.




RN 1033562-61-6 CAPLUS
CN 2-Propenoic acid, 3-[5-methoxy-2-[[[4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1033562-63-8 CAPLUS
CN 2-Propenoic acid, 3-[4-methoxy-2-[[[4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1033562-65-0 CAPLUS
CN 2-Propenoic acid, 3-[3-methoxy-2-[[[4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 1033562-67-2 CAPLUS
CN 2-Propenoic acid, 3-[4,5-dimethoxy-2-[[4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1033562-69-4 CAPLUS
CN 2-Propenoic acid, 3-[3,4,5-trimethoxy-2-[[4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1033562-71-8 CAPLUS
CN 2-Propenoic acid, 3-[3,4,5-trimethoxy-2-[[4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [X = (CR5aR5)m; Y = (CR4aR4)n; W = (CH2)p; m = 0-3; n = 1, 2; p = 0-2; R1 = aryl, heteroaryl; R2 = OH, O-alkyl, F; R3 = aryl, heteroaryl; R4, R4a = H, alkyl with provisios; Z = O, CH2, NRn; Rn = H, alkyl, cycloalkyl, etc.; R5, R5a = H, alkyl with provisios; R6 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of amine II and carboxylic acid III afforded phenylsulfonypiperidine IV. In bradykinin BK1 receptor assays, 278 examples of compds. I exhibited 0.0-100% inhibition at 10 mM.

II 1021204-90-9P 1021204-91-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylsulfonypiperidines as bradykinin 1 receptor modulators)


RN 1021204-90-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[[[(3,4-dichlorophenyl)sulfonyl]methylamino]phenyl]-, methyl ester (CA INDEX NAME)



RN 1021204-91-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[[[(3,4-dichlorophenyl)sulfonyl]methylamino]phenyl]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:502720 CAPLUS
DOCUMENT NUMBER: 148:495803
TITLE: Preparation of N-phenylsulfonypiperidines as bradykinin 1 receptor modulators
INVENTOR(S): Oberboersch, Stefan; Reich, Melanie; Schunk, Stefan; Hees, Sabine; Jostock, Ruth; Engels, Michael; Kless, Achim; Christoph, Thomas; Schiene, Klaus; Germann, Tienor; Bijsterveld, Edward
PATENT ASSIGNEE(S): Gruenthal GmbH, Germany
SOURCE: PCT Int. Appl., 14ipp.
CODEN: FIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008046573	A1	20080424	WO 2007-EP8927	20071015
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LI, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2666406	A1	20080424	CA 2007-2666406	20071015
EP 2086935	A1	20090312	EP 2007-818998	20071015
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, MI, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080249128	A1	20081009	US 2007-873065	20071016
PRIORITY APPLN. INFO.:			DE 2006-102006049412A	20061016
			US 2006-851740P	P 20061016
			WO 2007-EP8927	W 20071015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 148:495803
GI

L16 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:192837 CAPLUS
DOCUMENT NUMBER: 148:403061
TITLE: Heterocycles from ylides. Part XI. Synthesis of 2-substituted quinoline derivatives
AUTHOR(S): Cremonesi, Giuseppe; Dalla Croce, Piero; Fontana, Francesco; La Rosa, Concetta
CORPORATE SOURCE: Institute of Organic Chemistry "Alessandro Marchesini", Faculty of Pharmacy, Milan, I-20133, Italy
SOURCE: Heterocycles (2007), 74, 1015-1018
CODEN: HETCYM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:403061
AB The reaction of 2-N-phenylsulfonaminobenzaldehyde with stabilized alkylidene phosphoranes gave, through a Wittig condensation followed by reduction of intermediate alkenes and cyclization with polyphosphoric acid, quinoline derivs.
II 1015760-84-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-substituted quinoline derivs. by Wittig condensation of 2-N-phenylsulfonaminobenzaldehyde with alkylidene phosphoranes followed by reduction of intermediate alkenes and intramol. cyclization using polyphosphoric acid)
RN 1015760-84-5 CAPLUS
CN 2-Propenoic acid, 3-[2-[(phenylsulfonyl)amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:110366 CAPLUS
DOCUMENT NUMBER: 148:168595
TITLE: Preparation of bicyclic carbonyl indole compounds as antiinflammatory/analgesic agents and as COX-2 inhibitors
INVENTOR(S): Hayashi, Shigeo; Stevens, Rodney William; Nakao, Kazunari
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 35pp.
CODEN: EPFXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1065204	A1	20010103	EP 2000-305372	20000626
EP 1065204	B1	20020410		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, II, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 215945	T	20020415	AT 2000-305372	20000626
ES 2173846	T3	20021101	ES 2000-305372	20000626
US 6303628	B1	20011016	US 2000-605811	20000628
CA 2313122	A1	20010102	CA 2000-2313122	20000629
CA 2313122	C	20040824		
JP 2001031677	A	20010206	JP 2000-195996	20000629
JP 3333179	B2	20021007		
BR 200002936	A	20010403	BR 2000-2936	20000630
MX 200000605	A	20041209	MX 2000-6605	20000703
PRIORITY APPLN. INFO.: WO 1999-1B1243 W 19990702				
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 148:168595; MARPAT 148:168595				
GI				



GI




AB The title compds. I [A = alkylene or NR1; Z = is C(=L)R2 or SO2R3; U = CH or N; W and Y = CH2, O, S and NR1; m = 1-3; q and r = 0-2; X = halo, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy or the like; n = 0-4; L = O or S; R1 = H or alkyl; R2 = hydroxy, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkoxy, alkyl(cycloalkoxy) or the like; R3 = alkyl or haloalkyl] were prepared and claimed. E.g., a multi-step synthesis of Me {6-chloro-2-[(5,6,7,8-tetrahydroisoquinolin-3-yl)carbonyl]-1H-indol-3-yl}acetate, starting from Me trans-4-chloro-2-aminocinnamate, was given. Some exemplified compds. I were tested and showed IC50 of 0.001 μ M to 10 μ M with respect to inhibition of COX-2. This invention also provides a pharmaceutical composition comprising compound I useful for the



RN 231296-99-4 CAPLUS
CN 2-Fropenoic acid, 3-[2-[(phenylsulfonyl)amino]-5-(trifluoromethyl)phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1047331 CAPLUS
DOCUMENT NUMBER: 147:257718
TITLE: Synthesis of [2-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-carbonyl)-1H-indol-3-yl]acetic acids as potential COX-2 inhibitors
AUTHOR(S): Dubey, P. K.; Kumar, T. Venkateshwar; Reddanna, P.; Kumar, K. Anil
CORPORATE SOURCE: Department of Chemistry, College of Engineering, J.N.T. University, Hyderabad, 500 072, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2006), 45B(9), 2129-2132
CODEN: IJSCDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication and Information Resources
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:257718
AB The synthesis of the title compds. by means of internal Michael addition of o-tosylaminophenylacrylic acid Me esters with 6-(chloroacetyl)-2H-1,4-benzoxazin-4H-ones followed by hydrolysis is


treatment of a medical condition in which prostaglandins are implicated as pathogens.
IT 231296-58-5P 231296-65-4P 231296-73-4P
231296-99-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic carbonyl indoles as antiinflammatory/analgesic agents and COX-2 inhibitors)
RN 231296-58-5 CAPLUS
CN 2-Fropenoic acid, 3-[4-chloro-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 231296-65-4 CAPLUS
CN 2-Fropenoic acid, 3-[4,5-dichloro-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.




RN 231296-73-4 CAPLUS
CN 2-Fropenoic acid, 3-[5-methoxy-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.


reported.
IT 945862-20-4F 945862-22-6P 945862-24-8P
945862-26-0F
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [2-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-carbonyl)-1H-indol-3-yl]acetic acids as potential COX-2 inhibitors)
RN 945862-20-4 CAPLUS
CN 2-Fropenoic acid, 3-[2-[[4-methylphenyl)sulfonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 945862-22-6 CAPLUS
CN 2-Fropenoic acid, 3-[4,5-dimethoxy-2-[[4-methylphenyl)sulfonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)



RN 945862-24-8 CAPLUS
CN 2-Fropenoic acid, 3-[4-ethoxy-5-methoxy-2-[[4-methylphenyl)sulfonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 945862-26-0 CAPLUS
CN 2-Fropenoic acid, 3-[5-ethoxy-4-methoxy-2-[[4-methylphenyl)sulfonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:689544 CAPLUS
DOCUMENT NUMBER: 139:350598
TITLE: Synthesis of 2-acylindole-3-acetic acids: a novel base-mediated indole synthesis
AUTHOR(S): Nakao, Kazunari; Murata, Yoshinori; Koike, Hiroki; Uchida, Chikara; Kawamura, Kiyoshi; Mihara, Sachiko; Hayashi, Shigeo; Stevens, Rodney W.
CORPORATE SOURCE: Nagoya Laboratories, Discovery Chemistry Research, Global Research & Development, Pfizer Inc., 5-2 Taketoyo, Aichi, 470-2393, Japan
SOURCE: Tetrahedron Letters (2003), 44(39), 7269-7271
CODEN: TETLEA; ISSN: 0040-4039
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:350598
GI




GI



AB An efficient and expedient synthetic route to 2-acylindole-3-acetic acids, e.g., I, is described. A one-pot room-temperature indole ring construction via the in situ generation of indoline intermediate is reported.


II 231296-04-1P 231296-58-5P 231296-73-4P
231297-00-0P 618902-22-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acylindoleacetic acids via Wittig reaction of nitrobenzaldehydes with Me triphenylphosphoranylidene acetate followed by reduction, sulfonylation, base-mediated heterocyclization, desulfonylation, and ester hydrolysis)
RN 231296-04-1 CAPLUS
CN 2-Propenoic acid, 3-[5-chloro-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-58-5 CAPLUS
CN 2-Propenoic acid, 3-[4-chloro-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-73-4 CAPLUS
CN 2-Propenoic acid, 3-[5-methoxy-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231297-00-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 618902-22-0 CAPLUS
CN 2-Propenoic acid, 3-[4-methoxy-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.





OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:292359 CAPLUS
DOCUMENT NUMBER: 139:36409
TITLE: Efficient Synthesis of [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic Acid, a Novel COX-2 Inhibitor
AUTHOR(S): Caron, Stephane; Vazquez, Enrique; Stevens, Rodney W.; Nakao, Kazunari; Koike, Hiroki; Murata, Yoshinori
CORPORATE SOURCE: Chemical R&D, Pfizer Global Research Development, Groton, CT, 06340-8118, USA
SOURCE: Journal of Organic Chemistry (2003), 68(10), 4104-4107
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:36409
GI




GI




AB An efficient approach to the synthesis of 6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-ylacetic acid (I), a selective cyclooxygenase 2 (COX-2) inhibitor, was developed. The synthesis relied on a novel indole ring formation that involved an alkylation/1,4-addition/elimination/isomerization cascade. The entire sequence from sulfonamide II and α-bromo-4-chloroacetophenone to I could be executed in a single pot.

II 540734-09-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(condensation with bromoacetophenone; preparation of chloro(chlorobenzoyl)indoleacetic acid)
RN 540734-09-6 CAPLUS



CN 2-Propenoic acid, 3-[4-chloro-2-[(4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




II 540734-11-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (intramolecular heterocyclization) preparation of chloro(chlorobenzoyl)indoleacetic acid

RN 540734-11-0 CAPLUS

CN 2-Propenoic acid, 3-[4-chloro-2-[(2-(4-chlorophenyl)-2-oxoethyl][(4-methylphenyl)sulfonyl]amino]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT:

25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)

REFERENCE COUNT:

16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:

2003154382 CAPLUS

DOCUMENT NUMBER:

138:187795

TITLE:

Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as

antagonists of prostaglandin E2 (PEG2) receptors

Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru;

Narita, Masami; Ogawa, Mikio

INVENTOR(S):

Caplus, Ltd., 1009 pp.

SOURCE:

EC in Appl., 1009 pp.

DOCUMENT TYPE:

Patent

AB Carboxylic acid derivs. (I) and nontoxic salts thereof (wherein R1 = CO2H, CO2R4, CH2OH, COR5O2R6, CH2SO2NR5COR10, CH2NR5COR10, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = Cl-6 alkyl, hydroxy-Cl-4 alkyl, Cl-4 alkoxy-Cl-4 alkyl, carboxy-Cl-4 alkyl, etc.; R5, R9 = H, Cl-6 alkyl; R6 = Cl-6 alkyl, C3-15 mono-, di-, or tricyclic heterocyclyl, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, Cl-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or bicyclic carbocyclic ring, 3- to 12-membered mono- or bicyclic heterocyclic ring; R2 = Cl-6 alkyl, Cl-6 alkoxy, Cl-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo, m, n = 0,1,2; Q = Cl-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -Cl-4 alkylene-2-Cyc3, amino-Cl-4 alkyl, cyano-Cl-4 alkyl, acylamino-Cl-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHC(O), etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = Cl-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.) are prepared. These carboxylic acid derivs. include phenylpropanoic acid, phenylpropanoic acid, phenylpropanamide, phenylpropanamide, 3-oxoisindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propanoic acid, pyrazolylmethylpropanoic acid, (pyridinylmethylphenyl)propanoic acid, phenoxylacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinylmethylphenyl)propanamide, (pyrazolylmethyl)propanamide (oximidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propanamide, (thiophenylmethylphenyl)propanamide, (pyrazolylmethylphenyl)propanamide, (thiazolylaminomethylphenyl)propanamide, (thiazolylaminomethylphenyl)propanamide, (pyrazolylmethylphenoxy)acetamide, (phenoxyethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. 1 are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urticaria (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcaemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016254	A1	20030227	WO 2002-JF8120	20020808
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2457468	A1	20030227	CA 2002-2457468	20020808
AU 2002323916	A1	20030303	AU 2002-323916	20020808
EP 1431267	A1	20040623	EP 2002-755874	20020808
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, FI, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002011810	A	20040524	BR 2002-11810	20020808
CN 1551866	A	20041201	CN 2002-817376	20020808
HU 2004001963	A2	20050128	HU 2004-1963	20020808
HU 2004001963	A3	20060130		
NZ 531153	A	20051028	NZ 2002-531153	20020808
NZ 541950	A	20070223	NZ 2002-541950	20020808
RU 2315746	C2	20080127	RU 2004-106623	20020808
CN 101284713	A	20081015	CN 2008-10062260	20020808
ZA 2004000973	A	20050104	ZA 2004-973	20040205
NO 2004000564	A	20040510	NO 2004-564	20040206
MX 2004001253	A	20040603	MX 2004-1253	20040209
US 20060258728	A1	20061116	US 2004-486220	20040909
US 7491748	B2	20090217		

PRIORITY APPLN. INFO.:

JF 2001-241867 A 20010809
CN 2002-817376 A3 20020808
WO 2002-JF8120 W 20020808

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L6SUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:187795

GI



GI



or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)phenyl]butanoic acid inhibited the binding of [3H]EPGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, EP2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.


II 499151-02-9F

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499151-02-9 CAPLUS

CN 2-Propenoic acid, 3-[2-[methyl(phenyl)sulfonyl]amino]-4-(phenoxymethyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT:

20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)

REFERENCE COUNT:

14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:

2001:66213 CAPLUS

DOCUMENT NUMBER:

135:227024

TITLE:

Production method of FR 900482 analogs as antitumor agents

INVENTOR(S):

Fukuyama, Toru; Tokuyama, Hidetoshi

PATENT ASSIGNEE(S):

Foundation for Scientific Technology Promotion, Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 21 pp.

CODEN:

JKXXAF

DOCUMENT TYPE:

Japanese

LANGUAGE:


1

FAMILY ACC. NUM. COUNT:


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


JF 2001247573 A 20010911 JP 2000-107404 20000304
 JP 4287570 B2 20090701 JP 2000-107404 20000304
 PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): CASREACT 135:227024; MARPAT 135:227024
 GI



GI




AB Title compds. [I; R1, R2, R3, R4, R5 independently = H, hydrocarbon; X = O, NH], enantiomers, and intermediates are prepared. Title compds. are prepared as the aldose reductase inhibitors. Thus, the title compound I (R1 = CH3; R2 = CH3; R3 = H; R4 = H; X = NH) was prepared from 2-methoxy-4-methyl-6-azido-benzaldehyde, (C6H5)3P:CHCOOC2H5, and L-tartaric acid derivative via cyclization and reduction
 IT 359818-59-OP 359818-60-3P 359818-61-4P 359818-62-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (production method of FR 900482 analogs as antitumor agents)
 RN 359818-59-0 CAPLUS
 CN 2-Fropenoic acid, 3-[2-methoxy-4-methyl-6-[(4-nitrophenyl)sulfonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)




RN 359818-60-3 CAPLUS
 CN 2-Fropenoic acid, 3-[2-[[[(4S,5S)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,2-dimethyl-1,3-dioxolan-4-yl]methyl][(4-nitrophenyl)sulfonyl]amino]-6-methoxy-4-methylphenyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 359818-61-4 CAPLUS
 CN 2-Fropenoic acid, 3-[2-[[[(4S,5S)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl][(4-nitrophenyl)sulfonyl]amino]-6-methoxy-4-methylphenyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 359818-62-5 CAPLUS
 CN 2-Fropenoic acid, 3-[2-[[[(4S,5S)-5-[(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl][(4-nitrophenyl)sulfonyl]amino]-6-methoxy-4-methylphenyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


L16 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2001:495121 CAPLUS
 DOCUMENT NUMBER: 135:242045
 TITLE: Intramolecular 1,3-Dipolar Cycloaddition Strategy for Enantioselective Synthesis of FR-900482 Analogues
 AUTHOR(S): Kambe, Mika; Arai, Eri; Suzuki, Masashi; Tokuyama, Hidetoshi; Fukuyama, Tohru
 CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, The University of Tokyo CREST The Japan Science and Technology Corporation, Bunkyo-ku, Tokyo, 113-0033, Japan
 SOURCE: Organic Letters (2001), 3(16), 2575-2578
 CODEN: ORLEF7; ISSN: 1523-7060
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal

LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:242045
 AB Enantioselective synthesis of FR-900482 analogs is described. The key reaction of the synthesis is intramol. 1,3-dipolar cycloaddn. of a highly functionalized nitrile oxide with complete stereo- and regioselectivities to construct the eight-membered benzazocine ring.
 IT 359818-59-OP 360059-95-6P 360060-21-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (enantioselective synthesis of FR-900482 analogs via intramol. 1,3-dipolar cycloaddn. of nitrile oxide)
 RN 359818-59-0 CAPLUS
 CN 2-Fropenoic acid, 3-[2-methoxy-4-methyl-6-[(4-nitrophenyl)sulfonyl]amino]phenyl]-, ethyl ester (CA INDEX NAME)



RN 360059-95-6 CAPLUS
 CN 2-Fropenoic acid, 3-[2-[[[(4R,5R)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl][(4-nitrophenyl)sulfonyl]amino]-6-methoxy-4-methylphenyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.



RN 360060-21-5 CAPLUS
 CN 2-Fropenoic acid, 3-[2-[[[(4R,5R)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,2-dimethyl-1,3-dioxolan-4-yl]methyl][(4-nitrophenyl)sulfonyl]amino]-6-methoxy-4-methylphenyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.

Double bond geometry as shown.




RN 231296-65-4 CAPLUS
CN 2-Fropenoic acid, 3-[4,5-dichloro-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-68-7 CAPLUS
CN 2-Fropenoic acid, 3-[5-methyl-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-71-2 CAPLUS
CN 2-Fropenoic acid, 3-[5-fluoro-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-84-7 CAPLUS
CN 2-Fropenoic acid, 3-[4-ethyl-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-88-1 CAPLUS
CN 2-Fropenoic acid, 3-[5-(1-methylethyl)-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-91-6 CAPLUS
CN 2-Fropenoic acid, 3-[2-[(phenylsulfonyl)amino]-4-(trifluoromethyl)phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-73-4 CAPLUS
CN 2-Fropenoic acid, 3-[5-methoxy-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-76-7 CAPLUS
CN 2-Fropenoic acid, 3-[4-methoxy-2-[[4-methylphenyl]sulfonyl]amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-78-9 CAPLUS
CN 2-Fropenoic acid, 3-[5-ethyl-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-93-8 CAPLUS
CN 2-Fropenoic acid, 3-[5-(1,1-dimethylethyl)-2-[[4-methylphenyl]sulfonyl]amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-95-0 CAPLUS
CN 2-Fropenoic acid, 3-[2-[[4-methylphenyl]sulfonyl]amino]-5-(trifluoromethoxy)phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-97-2 CAPLUS
CN 2-Fropenoic acid, 3-[4-methyl-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231296-99-4 CAPLUS
CN 2-Fropenoic acid, 3-[2-[(phenylsulfonyl)amino]-5-(trifluoromethyl)phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231297-00-0 CAPLUS
CN 2-Fropenoic acid, 3-[2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231297-42-0 CAPLUS
CN 2-Fropenoic acid, 3-[4-chloro-5-fluoro-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231297-53-3 CAPLUS
CN 2-Fropenoic acid, 3-[4-chloro-2-[(phenylsulfonyl)amino]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231297-55-5 CAPLUS
CN 2-Fropenoic acid, 3-[5-acetyl-2-[(4-methylphenyl)sulfonyl]amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 231297-59-9 CAPLUS
CN 2-Fropenoic acid, 3-[4-fluoro-2-[(4-methylphenyl)sulfonyl]amino]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 231297-61-3 CAPLUS
CN 2-Fropenoic acid, 3-[5-(methylthio)-2-[(phenylsulfonyl)amino]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.





OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L16 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2009 ACS on SIN
ACCESSION NUMBER: 1994:54333 CAPLUS
DOCUMENT NUMBER: 120:54333
ORIGINAL REFERENCE NO.: 120:9915a,9918a
TITLE: Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors
INVENTOR(S): Ohtani, Mitsunori; Arita, Hitoshi; Sugita, Kenji; Matsura, Takaharu; Shirahase, Kazuhiro
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9312075	A1	19930624	WO 1992-JP1593	19921207
W: JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

EP 570594 A1 19931124 EP 1992-924883 19921207
EP 570594 B1 19970730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE
AT 156116 T 19970815 AT 1992-924883 19921207
ES 2107557 T3 19971201 ES 1992-924883 19921207
JP 3342485 B2 20021111 JP 1993-510775 19921207
US 5534654 A 19960709 US 1993-98272 19930803
PRIORITY APPLN. INFO.: JP 1991-350793 A 19911210
WO 1992-JP1593 W 19921207
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 120:54333; MARPAT 120:54333
GI




GI



AB The title compds. R2ONR1COXALYNR3BA2 (I) [A1 = (substituted) aromatic ring, aromatic heterocyclic ring; A2 = H, (substituted) aryl, aromatic heterocyclic ring; B = single bond, B1B2; B1 = CO, SO2; B2 = alkylene, alkenylene, etc.; X = (substituted) alkylene which may have O, S, N and may have unsatd. bond; Y = single bond, heteroatom, (substituted) alkylene which may contain heteroatom and may have unsatd. bond; X and N (which is linked to Y) may together form a moiety Q; R1 - R3 = H, (substituted) alkyl, aryl] were prepared. I inhibit hemangioendothelial cell growth, the development of a lymphocyte adhesion factor, and ras gene-induced cell transformation and are useful as inflammation and tumor inhibitors. Condensation of carboxylic acid (E)-II (R = OH) with NH2OH.HCl in DMF containing N-hydroxysuccinimide, N,N-dicyclohexylcarbodiimide, and Et3N gave (E)-II (R = NHOH). Hydroxamic acid (E)-III in vitro exhibited MIC of 0.039 μ M against ras gene-induced cell transformation.
IT 151721-04-9P 151721-05-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of inflammation and tumor inhibitor)
RN 151721-04-9 CAPLUS
CN 2-Fropenoic acid, 3-[4,5-dimethoxy-2-[(phenylsulfonyl)amino]phenyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 151721-05-0 CAPLUS
CN 2-Fropenoic acid, 3-[4,5-dimethoxy-2-[(phenylsulfonyl)amino]phenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

L16 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 1950:43600 CAPLUS
DOCUMENT NUMBER: 44:43600
ORIGINAL REFERENCE NO.: 44:83361,8337a-i,8338a-c
TITLE: Sulfonamides. III. Sulfanilamidocarboxyamides as intestinal antiseptics; the influence of pKa and hydrogen-bonding capacity
AUTHOR(S): Gorvin, John H.
CORPORATE SOURCE: Wellcome Labs., London
SOURCE: Journal of the Chemical Society (1949) 3304-11
CODEN: JCSO9; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. C.A. 40, 1151.3, 1152.1. Amides and imides of sulfanilamido aryl carboxylic acids have been prepared for examination as intestinal antiseptics,


mg./100 g. body weight) by mouth, in 10% gum-acacia mucilage, taking peripheral blood samples over a 6-hr. period, and estimating the sulfonamide content by a modified Bratton-Marshall method (cf. C.A. 33, 5017.4). From the absorption, the percentage drug unionized at pH 7.4 was calculated. The following values were obtained: o-sulfanilamidobenzamide, 80; m, 91; p, 80; 4-sulfanilamidobenzamide (XIII) N-Me derivative 83; N-Et, 86; N-Pr, 86; N-Bu, 86; N,N-di-Me, 86; III, 64; VIII amide, 89; XII, and N4-Me, Et, Pr, and Bu derivs., 99.9; 4-sulfanilamidophenyl cyanide, 58. The pKa values of a series of sulfonamides were determined in H2O at concentration 0.0025 N

and in 50% aqueous alc. at 0.01 N. The following results were obtained: sulfapyridine pKa/H2O 8.62, pKa/50% aqueous alc. 9.8; sulfathiazole, 7.41, 8.5; V amide, 7.1, 8.1; III, 7.65, 9.15; o-sulfanilamidobenzamide, 8.0, 9.4; m, 8.45, 10.2; p, 8.02, 9.9; N-Me XIII, 8.1, 10; N-Et XIII, 8.2, 10; N, N-di-Me XIII, 8.5, 10.15; sulfanilylsulfanilamide, 7.63, 9.45; VIII amide, 8.3, 10.2; p-sulfanilamidophenyl cyanide, 7.55, 9. The following values for pKa/H2O were determined: sulfanilamide, 10.7; XII, 10.35; N4-Me XII, 10.4; N4-Et, 10.25; N4-Pr and N4-Bu 10.4. The poor absorption of p-H2NC2H4SO2NHAc in contrast to the relatively good absorption of sulfanilamide seems to indicate that H-bonding properties of the CONH2 group, rather than pKa value or mol. size, are responsible for the low absorption of N-sulfanilamidocarboxyamides.

IT 1089688-22-1P
RL: SPN (Synthetic preparation); PRP (Properties); PREP (Preparation) (Sulfonamides. III. Sulfanilamidocarboxyamides as intestinal antiseptics; the influence of pKa and hydrogen-bonding capacity)
RN 1089688-22-1 CAPLUS
CN 2-Fropenoic acid, 3-[2-[[[4-aminophenyl)sulfonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)



IT 854884-18-7, Cinnamic acid, o-sulfanilamido- (and derivs.)
RN 854884-18-7 CAPLUS
CN 2-Fropenoic acid, 3-[2-[[[4-aminophenyl)sulfonyl]amino]phenyl]- (CA INDEX NAME)



=> logoff hold

(FILE 'HOME' ENTERED AT 11:56:11 ON 07 DEC 2009)

and an attempt made to correlate pharmacol. activity, pKa, and degree of absorption from the gut. 5-Sulfanilamidosalicylic acid (I), m. 222-3°, was prepared by shaking mechanically at 40-50° Na 5-aminosalicylate (7.65 g. of the acid in 80 cc. 6% aqueous NaOH solution) with an aqueous suspension of 11.7 g. p-AcNHCH6H4SO2Cl (II), adding 5 g. NaOH at the conclusion of reaction, boiling the solution 2 hrs., treating with Na2S2O4, adjusting to pH 2-3, purifying the precipitated I (90%) with decolorizing C and Na2S2O4, and reprecip. I from NH3 solution (cf. Crossley, et al., C.A. 32, 8381.6; Fr. 830,754; C.A. 33, 1448.4; U.S. 2, 270, 676; C.A. 36, 3324.3); N4-Ac derivative, m. about 265° (decomposition); Me ester (87%), m. 188-9°; Et ester (80-85%), m. 186-7° (from aqueous alc.); amide (III) (83%), m. 221-2.5° (from 12.9 g. I Me ester left 5 days with 80 cc. aqueous NH3 (d. (0.880))); N4-Ac derivative of III, m. 272-3°. 3-Aminosalicylic acid (IV) was prepared (50%) by reduction of Na 3-nitrosalicylate with Na2S2O4 in warm aqueous solution, adjusting the pH to 5, and evaporating the solution in vacuo until IV separated. The following compds. were prepared by similar methods: 3-sulfanilamidosalicylic acid (V) (56%), m. 217-18° (decomposition); [N4-Ac derivative, m. 265° (decomposition); Et ester (61%), m. 176.5°; amide (88%), m. 193-4°]; 3-sulfanilamidocinnamic acid (VI) (60%), m. 214° (cf. C.A. 33, 2495.9) (Et ester, 94%, m. 147-8°; amide, 96%, m. 247°); Et 4-aminocinnamate (VII), m. 73°, prepared in 50% yield by reducing 7.5 g. of the 4-nitro compound in 20 cc. hot glacial AcOH with 25 g. SnCl2 in 20 cc. concentrated HCl, boiling until solution was completed, pouring onto ice, making alkaline with NaOH, dissolving the crude precipitated ester in alc., treating with Na2S2O4, and diluting with H2O. 4-Sulfanilamidocinnamic acid (VIII), m. 247° (decomposition), was best prepared by warming VII with II in pyridine for 0.5 hr., giving Et 4-(N4-acetylsulfanilamidocinnamate, m. 211°, saponified to VIII, m. 247° (decomposition) (Me ester, m. 257°; Et ester, m. 221-2°; amide, m. 224.5°). The following were obtained similarly: 2-sulfanilamidocinnamic acid (92%), m. 256° (N4-Ac derivative, m. 215°; Me ester, m. 190-191°; amide, m. 237-238°). 3-Aminophthalimide (2.4 g.), prepared from the 3-nitro derivative with Na2S2O4, was warmed with 3.5 g. II in pyridine at 80° for 2 hrs., giving 72% 3-(N4-acetylsulfanilamidophthalimide, m. 240-1°, which was deacetylated by stirring 11 g. with 100 cc. concentrated HCl for 5 min. and pouring into ice to give 3-sulfanilamidophthalimide, m. 219° (from 25% aqueous alc.). 4-Sulfanilamidophthalimide (40%), m. 266°, was prepared analogously, but deacetylation of the Ac derivative, m. 295°, required 1-2 hrs. Et 3-aminopicolinate, m. 131-3°, prepared from the acid, was allowed to react (1.66 g.) for 1 hr. at 80° with 3 g. II in pyridine, the excess pyridine evaporated, and the residue taken up in dilute HCl and precipitated with NaOH solution, giving Et 3-(N4-acetylsulfanilamidopicolinate (IX) (64%), m. 187-8° (amide (X), yellowish prisms, m. 243-4°), deacetylated to 3-sulfanilamidopicolinate, m. 212-13°. Et sulfanilamidoacetate (XI) shaken with aqueous NH3 for 1 hr. gave o-sulfanilamidoacetamide (XII), m. 155° (from alc.); XI dissolved in an aliphatic amine, let stand 3 days, and neutralized with NaOH gave the following N4-alkyl derivs.: Me, m. 147° and 162-3° (dimorphic); Et, m. 126-7°; Fr, m. 140°; Bu, m. 109-10°. The following relative rates of ammonolysis were determined by sealing the ester (0.0025 mol.) in a glass tube with aqueous NH3 (5 cc., d. 0.885) at room temperature: Et 4-sulfanilamidobenzoate, 148 days, 56% reacted; VIII Et ester, 148 days, 61%; Me 4-sulfanilamidobenzoate, 15 days, 83%; VIII Me ester, 15 days, 53%; Et 3-sulfanilamidobenzoate, 2.8 days, 55%; VI Et ester, 2.5 days, 100%; I Et ester, 2.5 days, 100%; Me 3-sulfanilamidobenzoate, 1.7 days, 80%; I Me ester, 1.7 days, 99.5%. The absorption of sulfonamides in mice was determined by administering the drug (25

L1 FILE 'REGISTRY' ENTERED AT 11:57:52 ON 07 DEC 2009
L2 STRUCTURE UPLOADED
L3 D
L4 15 SEA FILE-REGISTRY SSS SAM L1
L5 STRUCTURE UPLOADED
L6 D
L7 14 SEA FILE-REGISTRY SSS SAM L3
L8 292 SEA FILE-REGISTRY SSS FUL L3
L9 254 SEA FILE-REGISTRY SPE=ON ABB=ON FLU=ON L5 AND CAPLUS/LC
L10 0 SEA FILE-REGISTRY SPE=ON ABB=ON FLU=ON L5 NOT L5
L11 0 SEA FILE-REGISTRY SPE=ON ABB=ON FLU=ON L5 NOT L5
L12 38 SEA FILE-REGISTRY SPE=ON ABB=ON FLU=ON L5 NOT L6
L13 D L9 1-38
L14 FILE 'CAPLUS' ENTERED AT 12:02:52 ON 07 DEC 2009
L15 48 SEA FILE=CAPLUS SPE=ON ABB=ON FLU=ON L6
L16 D L10 IBIB GI ABS HITSTR 1-48
L17 FILE 'REGISTRY' ENTERED AT 12:37:15 ON 07 DEC 2009
L18 STRUCTURE UPLOADED
L19 D
L20 3 SEA FILE-REGISTRY SUB=L5 SSS SAM L11
L21 64 SEA FILE-REGISTRY SUB=L5 SSS FUL L11
L22 61 SEA FILE-REGISTRY SPE=ON ABB=ON FLU=ON L13 AND CAPLUS/LC
L23 3 SEA FILE-REGISTRY SPE=ON ABB=ON FLU=ON L13 NOT L14
L24 D L15 1-3
L25 FILE 'CAPLUS' ENTERED AT 12:38:09 ON 07 DEC 2009
L26 15 SEA FILE=CAPLUS SPE=ON ABB=ON FLU=ON L14
L27 D L16 IBIB GI ABS HITSTR 1-15
L28 COST IN U.S. DOLLARS SINCE FILE TOTAL
L29 ENTRY 85.60 SESSION 886.93
L30 FULL ESTIMATED COST
L31 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
L32 ENTRY -12.30 SESSION -51.66
L33 CA SUBSCRIBER PRICE
L34
L35
L36
L37
L38
L39
L40
L41
L42
L43
L44
L45
L46
L47
L48
L49
L50
L51
L52
L53
L54
L55
L56
L57
L58
L59
L60
L61
L62
L63
L64
L65
L66
L67
L68
L69
L70
L71
L72
L73
L74
L75
L76
L77
L78
L79
L80
L81
L82
L83
L84
L85
L86
L87
L88
L89
L90
L91
L92
L93
L94
L95
L96
L97
L98
L99
L100
L101
L102
L103
L104
L105
L106
L107
L108
L109
L110
L111
L112
L113
L114
L115
L116
L117
L118
L119
L120
L121
L122
L123
L124
L125
L126
L127
L128
L129
L130
L131
L132
L133
L134
L135
L136
L137
L138
L139
L140
L141
L142
L143
L144
L145
L146
L147
L148
L149
L150
L151
L152
L153
L154
L155
L156
L157
L158
L159
L160
L161
L162
L163
L164
L165
L166
L167
L168
L169
L170
L171
L172
L173
L174
L175
L176
L177
L178
L179
L180
L181
L182
L183
L184
L185
L186
L187
L188
L189
L190
L191
L192
L193
L194
L195
L196
L197
L198
L199
L200
L201
L202
L203
L204
L205
L206
L207
L208
L209
L210
L211
L212
L213
L214
L215
L216
L217
L218
L219
L220
L221
L222
L223
L224
L225
L226
L227
L228
L229
L230
L231
L232
L233
L234
L235
L236
L237
L238
L239
L240
L241
L242
L243
L244
L245
L246
L247
L248
L249
L250
L251
L252
L253
L254
L255
L256
L257
L258
L259
L260
L261
L262
L263
L264
L265
L266
L267
L268
L269
L270
L271
L272
L273
L274
L275
L276
L277
L278
L279
L280
L281
L282
L283
L284
L285
L286
L287
L288
L289
L290
L291
L292
L293
L294
L295
L296
L297
L298
L299
L300
L301
L302
L303
L304
L305
L306
L307
L308
L309
L310
L311
L312
L313
L314
L315
L316
L317
L318
L319
L320
L321
L322
L323
L324
L325
L326
L327
L328
L329
L330
L331
L332
L333
L334
L335
L336
L337
L338
L339
L340
L341
L342
L343
L344
L345
L346
L347
L348
L349
L350
L351
L352
L353
L354
L355
L356
L357
L358
L359
L360
L361
L362
L363
L364
L365
L366
L367
L368
L369
L370
L371
L372
L373
L374
L375
L376
L377
L378
L379
L380
L381
L382
L383
L384
L385
L386
L387
L388
L389
L390
L391
L392
L393
L394
L395
L396
L397
L398
L399
L400
L401
L402
L403
L404
L405
L406
L407
L408
L409
L410
L411
L412
L413
L414
L415
L416
L417
L418
L419
L420
L421
L422
L423
L424
L425
L426
L427
L428
L429
L430
L431
L432
L433
L434
L435
L436
L437
L438
L439
L440
L441
L442
L443
L444
L445
L446
L447
L448
L449
L450
L451
L452
L453
L454
L455
L456
L457
L458
L459
L460
L461
L462
L463
L464
L465
L466
L467
L468
L469
L470
L471
L472
L473
L474
L475
L476
L477
L478
L479
L480
L481
L482
L483
L484
L485
L486
L487
L488
L489
L490
L491
L492
L493
L494
L495
L496
L497
L498
L499
L500
L501
L502
L503
L504
L505
L506
L507
L508
L509
L510
L511
L512
L513
L514
L515
L516
L517
L518
L519
L520
L521
L522
L523
L524
L525
L526
L527
L528
L529
L530
L531
L532
L533
L534
L535
L536
L537
L538
L539
L540
L541
L542
L543
L544
L545
L546
L547
L548
L549
L550
L551
L552
L553
L554
L555
L556
L557
L558
L559
L560
L561
L562
L563
L564
L565
L566
L567
L568
L569
L570
L571
L572
L573
L574
L575
L576
L577
L578
L579
L580
L581
L582
L583
L584
L585
L586
L587
L588
L589
L590
L591
L592
L593
L594
L595
L596
L597
L598
L599
L600
L601
L602
L603
L604
L605
L606
L607
L608
L609
L610
L611
L612
L613
L614
L615
L616
L617
L618
L619
L620
L621
L622
L623
L624
L625
L626
L627
L628
L629
L630
L631
L632
L633
L634
L635
L636
L637
L638
L639
L640
L641
L642
L643
L644
L645
L646
L647
L648
L649
L650
L651
L652
L653
L654
L655
L656
L657
L658
L659
L660
L661
L662
L663
L664
L665
L666
L667
L668
L669
L670
L671
L672
L673
L674
L675
L676
L677
L678
L679
L680
L681
L682
L683
L684
L685
L686
L687
L688
L689
L690
L691
L692
L693
L694
L695
L696
L697
L698
L699
L700
L701
L702
L703
L704
L705
L706
L707
L708
L709
L710
L711
L712
L713
L714
L715
L716
L717
L718
L719
L720
L721
L722
L723
L724
L725
L726
L727
L728
L729
L730
L731
L732
L733
L734
L735
L736
L737
L738
L739
L740
L741
L742
L743
L744
L745
L746
L747
L748
L749
L750
L751
L752
L753
L754
L755
L756
L757
L758
L759
L760
L761
L762
L763
L764
L765
L766
L767
L768
L769
L770
L771
L772
L773
L774
L775
L776
L777
L778
L779
L780
L781
L782
L783
L784
L785
L786
L787
L788
L789
L790
L791
L792
L793
L794
L795
L796
L797
L798
L799
L800
L801
L802
L803
L804
L805
L806
L807
L808
L809
L810
L811
L812
L813
L814
L815
L816
L817
L818
L819
L820
L821
L822
L823
L824
L825
L826
L827
L828
L829
L830
L831
L832
L833
L834
L835
L836
L837
L838
L839
L840
L841
L842
L843
L844
L845
L846
L847
L848
L849
L850
L851
L852
L853
L854
L855
L856
L857
L858
L859
L860
L861
L862
L863
L864
L865
L866
L867
L868
L869
L870
L871
L872
L873
L874
L875
L876
L877
L878
L879
L880
L881
L882
L883
L884
L885
L886
L887
L888
L889
L890
L891
L892
L893
L894
L895
L896
L897
L898
L899
L900
L901
L902
L903
L904
L905
L906
L907
L908
L909
L910
L911
L912
L913
L914
L915
L916
L917
L918
L919
L920
L921
L922
L923
L924
L925
L926
L927
L928
L929
L930
L931
L932
L933
L934
L935
L936
L937
L938
L939
L940
L941
L942
L943
L944
L945
L946
L947
L948
L949
L950
L951
L952
L953
L954
L955
L956
L957
L958
L959
L960
L961
L962
L963
L964
L965
L966
L967
L968
L969
L970
L971
L972
L973
L974
L975
L976
L977
L978
L979
L980
L981
L982
L983
L984
L985
L986
L987
L988
L989
L990
L991
L992
L993
L994
L995
L996
L997
L998
L999
L1000

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:39:04 ON 07 DEC 2009